Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients

NCT02655770 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication liraglutide can improve heart function in adults with type 2 diabetes who have diastolic dysfunction, as measured by cardiac MRI.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 40 people

Who can join Ages 18–80 · all sexes

Timeline Started 2016-02 · est. completion 2019-12

Where 1 site · Denmark

What this study is testing ClinicalTrials.gov NCT02655770 ↗

Description as written by the study sponsor.

The purpose of this study is to determine whether liraglutide a GLP-1 analogue are effective in the treatment of diastolic dysfunction in type 2 diabetes patients analyzed by cardiac MRI. Secondary if the treatment has any effect on the perfusion of the heart on a cardiac-MRI.

Treatments tested

Liraglutide also known as Victoza Drug
Placebo Drug

Main thing measured	Change in diastolic properties as assessed by CMR.
Sponsor	Rigshospitalet, Denmark
Conditions studied	Diabetes Mellitus Type 2, Diastolic Dysfunction, Cardiac MRI, Myocardial Perfusion
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02655770 ↗